Phase 2/3 Multistage Multicenter Randomized Double-Blind Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Go Back to All Clinical Trials

Phase 2/3 Multistage Multicenter Randomized Double-Blind Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Brief description of study

The purpose of this study is to see if nipocalimab is safe and useful for treating participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This is the first study where nipocalimab is being administered to participants with CIDP.

Clinical Study Identifier: s23-00487

ClinicalTrials.gov Identifier: NCT05327114

Principal Investigator: Mark Gudesblatt.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies